Bionano genomics announces release of version 6.2 of its nxclinical software with significant new capabilities for cancer research applications including hrd analysis

Version includes a powerful capability for genomic scar analysis for assessments of homologous recombination deficiency (hrd) that provides an efficient, consistent approach for analysis of tumor biomarkers used in pharmacogenomics and other cancer research version includes a powerful capability for genomic scar analysis for assessments of homologous recombination deficiency (hrd) that provides an efficient, consistent approach for analysis of tumor biomarkers used in pharmacogenomics and other cancer research
BNGO Ratings Summary
BNGO Quant Ranking